By Sean P. McConnell, Jonathan L. Swichar, Bradley A. Wasser and Nina Kalandadze
Last week, the Federal Trade Commission announced a settlement with Caremark Rx LLC and Zinc Health Services LLC in the agency’s administrative case against the nation’s three largest pharmacy benefit managers. Under the terms of the settlement, Caremark agreed to make certain structural changes to its pharmaceutical pricing and reimbursement practices. The Caremark settlement has distinct implications for participants across the pharmaceutical supply chain, and each should take specific steps to evaluate exposure and mitigate risk.
Read the full Alert on the Duane Morris LLP website.